Shelley R. Salpeter, MD, Ji Cheng, M.Sc. Buckley and Edwin E. Salpeter, PhD .The American Journal of Medicine, Volume 122, Number 11
An article published in November 2009 by the American Journal of Medicine reports that researchers conducting a meta-analysis of available data using Bayesian methods have come to the conclusion that will almost certainly reduce mortality among young women post-menopause. For over sixty years, HRT has been widely used for the treatment of estrogen deficiency in menopause. There was a justification based HRT increases the longevity of existing routines in postmenopausal women. However, the publication in 2002 of an important study, Women’s Health Initiative , reported an increased risk of certain outcomes in older women, with no increase in mortality. This started a debate on the potential advantages and disadvantages of HRT.
Shelley R. Salpeter, MD, wrote ‘It ‘clear that these results should be interpreted in the light of the potential benefits and disadvantages of hormone therapy. The cardiovascular benefit is the result of small increases and greater absolute reduction of events. The advantage of all deaths among young women in randomized clinical trials and observational studies indicate that the reduction in mortality due to illness coronary fractures and colon cancer offset the increase in deaths from breast cancer, stroke and pulmonary embolism.
In addition to this benefit in mortality, hormone therapy in younger women offers a better quality of life measures, at least in the early of treatment. ‘